While the cumulative risk of relapse was reduced by dexamethasone in both ALL phenotypes, it was most pronounced among patients with T-ALL (6% vs. 20%; p=0.003) and in those with ETV6-RUNX1 (4% vs. 13%; p<0.001) who had a good response to the prednisone prophase. The gene discussed is RUNX1; the disease is acute lymphoblastic leukemia.